Molecular profiling residual disease from early stage HER2 positive breast cancer treated with neoadjuvant chemo- and anti-HER2 therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1123212

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chemotherapy given prior to surgery can often inform us if a breast tumour is sensitive or resistant to therapy by the amount of disease remaining at time of surgery. We have further shown that the immune response is also important in these patients. In this study we propose to analyse the tumour samples that remain after chemotherapy in order to understand possible resistance mechanisms as well as how the immunity influences survival of HER2-positive breast cancer patients

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $467,108.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

breast cancer | cancer immunology | genomics | oncology | therapeutic agents

Related Links